SCHEMBL4891690

SCHEMBL4891690

c1ccc(COc2ccccc2-c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.59
MAPT P10636 2/20 0.59
AHR P35869 1/20 0.59
HTT P42858 1/20 0.59
PI4KB Q9UBF8 1/20 0.59
CLK4 Q9HAZ1 7/20 0.56
CYP1A2 P05177 6/20 0.56
CYP3A4 P08684 6/20 0.56
USP2 O75604 5/20 0.56
CYP2D6 P10635 5/20 0.56
CYP2C19 P33261 4/20 0.56
ALDH1A1 P00352 4/20 0.56
TSHR P16473 4/20 0.56
LMNA P02545 3/20 0.56
CYP2C9 P11712 2/20 0.56
HIF1A Q16665 2/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
KMT2A Q03164 1/20 0.53
EGFR P00533 7/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886091 0.88 EGFR (0.62) MAPK1MAPTAHRHTTPI4KB
SCHEMBL17075840 0.84 EGFR (0.59) MAPK1MAPTAHRHTTPI4KB
SCHEMBL14026142 0.84 MAPK1 (0.72) MAPK1MAPTAHRHTTPI4KB
SCHEMBL4891700 0.83 CLK4 (0.67) MAPK1MAPTAHRHTTPI4KB
SCHEMBL4008515 0.82 MAPT (0.80) MAPK1MAPTAHRHTTPI4KB
SCHEMBL4892996 0.82 PI4KB (0.57) MAPK1MAPTAHRHTTPI4KB
SCHEMBL17075865 0.81 EGFR (0.61) EGFRERBB2
SCHEMBL17075814 0.78 MAPK1 (0.63) MAPK1MAPTAHRHTTPI4KB
SCHEMBL4007152 0.78 MAPK1 (0.72) MAPK1MAPTAHRHTTPI4KB
SCHEMBL4931410 0.78 MAPT (0.66) MAPK1MAPTAHRHTTPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPK1 1945/4885MAPT 2064/4885AHR 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.